CLAIMS

1. Use of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) in the manufacture of a medicament for the treatment of cancer, wherein the FGFR1 ECD is to be administered in combination with docetaxel.

2. The use according to claim 1, wherein the FGFR1 ECD is to be administered in combination with at least one additional agent selected from paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, etoposide, topotecan, a VEGF antagonist, a VEGF trap, an anti-VEGF antibody, and bevacizumab.

3. The use according to claim 1 or 2, wherein the FGFR1 ECD comprises an amino acid sequence selected from SEQ ID NOs: 1 to 4.

4. The use according to claim 1, 2 or 3, wherein the FGFR1 ECD further comprises a fusion partner.

5. The use according to claim 4, wherein the FGFR1 ECD fusion partner is an Fc.

6. The use according to claim 5, wherein the FGFR1 ECD and Fc comprise a sequence selected from SEQ ID NO: 5 and SEQ ID NO: 6.

7. A dosage pack comprising at least one component selected from: (i) a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD), (ii) a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) fusion molecule, and (iii) docetaxel, wherein the dosage pack further comprises instructions for concurrently administering an FGFR1 ECD and/or FGFR1 ECD fusion molecule and the docetaxel to a patient.

CLAIMS

1. A method of treating cancer comprising administering to a subject a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, etoposide, topotecan, a VEGF antagonist, a VEGF trap, an anti-VEGF antibody, and bevacizumab.

2. The method of claim 1, wherein the FGFR1 ECD further comprises a fusion partner.

3. The method of claim 1 or 2, wherein the at least one additional therapeutic agent is docetaxel.

4. The method of claim 1 or 2, wherein the at least one additional therapeutic agent is paclitaxel.

5. The method of claim 1 or 2, wherein the at least one additional therapeutic agent is cisplatin.

6. The method of claim 1 or 2, wherein the at least one additional therapeutic agent is pemetrexed.

7. The method of claim 1 or 2, wherein the at least one additional therapeutic agent is vincristine.

8. The method of claim 1 or 2, wherein the at least one additional therapeutic agent is 5-FU.

9. The method of claim 1 or 2, wherein the at least one additional therapeutic agent is topotecan.

10. The method of any one of claims 1-9, wherein the method comprises administering to the subject at least two additional therapeutic agents selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, etoposide, topotecan, a VEGF antagonist, a VEGF trap, an anti-VEGF antibody, and bevacizumab.

11. The method of claim 10, wherein one of the at least two additional therapeutic agents is paclitaxel, oxaliplatin, 5-FU, or bevacizumab.

12. The method of claim 10, wherein the at least two additional therapeutic agents are paclitaxel and carboplatin.

13. The method of claim 10, wherein the at least two additional therapeutic agents are oxaliplatin and 5-FU.

14. The method of claim 10, wherein the at least two additional therapeutic agents are

doxorubicin and paclitaxel

15. The method of claim 10, wherein the at least two additional therapeutic agents are 5-FU and leucovorin.

16. The method of claim 10, wherein the at least two additional therapeutic agents are bevacizumab and 5-FU.

17. The method of claim 10, wherein the at least two additional therapeutic agents are cisplatin and etoposide.

18. The method of any one of claims 1- 17, wherein the FGFR1 ECD comprises an amino acid sequence selected from SEQ ID NOs: 1 to 4.

19. The method of any one of claims 2-18, wherein the FGFR1 ECD further comprises a fusion partner and the fusion partner is an Fc.

20. The method of claim 19, wherein the FGFR1 ECD and Fc comprise a sequence selected from SEQ ID NO: 5 and SEQ ID NO: 6.

21. A dosage pack comprising at least one component selected from: (i) a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD), (ii) a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) fusion molecule, and (iii) at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, etoposide, topotecan, a VEGF antagonist, a VEGF trap, an anti-VEGF antibody, and pemetrexed, wherein the dosage pack further comprises instructions for administering an FGFR1 ECD and/or FGFR1 ECD fusion molecule and the at least one additional therapeutic to a patient.

22. A combination of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, etoposide, topotecan, and bevacizumab, for use in treatment of cancer.

23. A combination of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and at least two additional therapeutic agents selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, etoposide, topotecan, a VEGF antagonist, a VEGF trap, an anti-VEGF antibody, and bevacizumab, for use in treatment of cancer.